CD8A and neoplasm: However, the combination of anti-mPD-1 with either 10 or 30 mg/kg of SNS-101-m2 significantly increased CD8+ T-cells to 19.3% and 26.4% (both P < 0.0001), respectively, correlating with the observed anti-tumor efficacy.